These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33377680)

  • 1. [The use of alfuzosin in the treatment of patients with acute urinary retention].
    Martov AG; Ergakov DV
    Urologiia; 2020 Dec; (6):58-63. PubMed ID: 33377680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
    Mariappan P; Brown DJ; McNeill AS
    J Urol; 2007 Aug; 178(2):573-7; discussion 577. PubMed ID: 17570437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
    Shah T; Palit V; Biyani S; Elmasry Y; Puri R; Flannigan GM
    Eur Urol; 2002 Oct; 42(4):329-32; discussion 332. PubMed ID: 12361896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
    McNeill SA; Daruwala PD; Mitchell ID; Shearer MG; Hargreave TB
    BJU Int; 1999 Oct; 84(6):622-7. PubMed ID: 10510105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
    Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
    Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
    Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA
    Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
    Desgrandchamps F; De La Taille A; Doublet JD;
    BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign prostatic hyperplasia: mode of presentation and postoperative outcome.
    Khan M; Khan AL; Khan S; Nawaz H
    J Pak Med Assoc; 2005 Jan; 55(1):20-3. PubMed ID: 15816691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.
    Palit V; Shah T; Biyani CS; Elmasry Y; Sarkar R; Flannigan GM; Puri R
    Int Urol Nephrol; 2005; 37(3):507-10. PubMed ID: 16307331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of intravesical prostatic protrusion on the outcome of trial without catheter in patients with acute urinary retention from benign prostatic hyperplasia at Jos University Teaching Hospital, Nigeria: a prospective observational study.
    Oshagbemi AO; Ofoha CG; Akpayak IC; Shuaibu SI; Dakum NK; Ramyil VM
    Pan Afr Med J; 2022; 42():246. PubMed ID: 36303820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study.
    Gujral S; Abrams P; Donovan JL; Neal DE; Brookes ST; Chacko KN; Wright MJ; Timoney AG; Peters TJ
    J Urol; 2000 Jul; 164(1):59-64. PubMed ID: 10840425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
    Maldonado-Ávila M; Manzanilla-García HA; Sierra-Ramírez JA; Carrillo-Ruiz JD; González-Valle JC; Rosas-Nava E; Guzman-Esquivel J; Labra-Salgado IR
    Int Urol Nephrol; 2014 Apr; 46(4):687-90. PubMed ID: 24061764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
    McNeill SA; Hargreave TB;
    J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of men with a first episode of acute urinary retention due to benign prostatic enlargement.
    Abeygunasekera AM; de Silva S; Gurusingha A; Wijeratne S
    Ceylon Med J; 2001 Dec; 46(4):124-5. PubMed ID: 12164028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
    Roehrborn CG
    Prostate Cancer Prostatic Dis; 2006; 9(2):121-5. PubMed ID: 16304557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.